CQN-CA-NAX
14.1.2021 09:03:34 CET | Business Wire | Press release
Please replace the logo in the release dated January 13, 2021 with the accompanying corrected logo.
The release reads:
NAX LAUNCHES AS FIRST PLATFORM TO CREATE CORPORATE ASSET-BACKED PRODUCTS, VENTURES AND SECURITIES
- Company founded by Jeff Schumacher
- Company already valued at over $300m USD
New Asset Exchange (NAX), a company that brings liquidity to corporate assets, has formally launched today after two and a half years in stealth development. It has established a new model for launching corporate asset-backed products, ventures and securities. NAX is founded by serial entrepreneur Jeff Schumacher.
NAX combines the software and the method to identify, build, launch and scale asset-backed products, ventures and securitized assets for institutional trading. NAX has secured $65m USD to date in investment from 12 institutional, family office and corporate investors across North America, Europe and Asia, valuing the company at over $300m USD. It launches with a global team based in North America and Europe.
NAX has developed software for digital, micro and platform services, as well as cloud commerce that can be utilized to rapidly market test fully compliant products, tradable securities and marketplaces. The firm will be announcing a series of milestones in the coming months to match its ambitious growth plans.
NAX is already working with leading global businesses in multiple industries including energy, healthcare and consumer goods to launch corporate asset-backed products, and is supported by operating partners from global leaders in trading, banking and underwriting to deliver the requisite infrastructure.
NAX CEO and founder Jeff Schumacher, previously founded and scaled BCG Digital Ventures, with the company becoming one of the largest foundries in the world, creating more than 100 businesses and growing to over 1,000 employees in less than six years. He also founded Axon Advisory Partners, before selling it to Booz & Co., creating Booz Digital, which was then acquired by PwC. Schumacher was previously a Partner at McKinsey, and also EVP, CMO and CSO at Sports Authority, a Leonard Green Partners portfolio company.
Jeff Schumacher, CEO and Founder, NAX said: “We are building upon a decade of learnings from working with the world's leading financial exchanges and institutions. With NAX, we are bringing financial innovation across sectors to create value in markets that otherwise would not exist.”
Since its inception, NAX has attracted several high-profile business figures to its Board, including Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank, and Heiner Leisten, Leisten & Cie. Family Office CEO and previously Senior Partner at BCG, among others.
Frank Strauß, Independent Board Member, NAX said: “In today’s world, financial innovation is the bedrock upon which successful ventures are created. Jeff’s vision for NAX is what attracted me to supporting the company in applying financial innovation to corporate assets and ultimately unlocking significant value from those assets.”
Francisco Arcilla, Partner, TNF Investments, which led the latest NAX fundraising round, said: “As an international investment firm that prides itself on being a catalyst for innovation and industry disruption, we were instantly captivated by NAX and its disruptive approach to asset creation and value generation. We were very excited to lead the latest round of funding for NAX, and we are equally enthusiastic about the prospect of the many ventures and further investment opportunities that NAX will create.“
NAX operates from its headquarters in Manhattan Beach, CA for North America and Paris, France for Europe, with further locations in Palo Alto, New York, London, and Frankfurt. In 2021, it will be expanding to Singapore, Tokyo and Sydney.
About NAX
NAX is a platform to create asset-backed products, ventures and securities for the world's leading institutions. We co-lead the commercialization of these initiatives with our partners.
For more information, visit http://www.naxgrp.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom